Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth Sells 8,637 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 8,637 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $19.98, for a total value of $172,567.26. Following the completion of the sale, the chief financial officer now owns 73,849 shares of the company’s stock, valued at approximately $1,475,503.02. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Kory James Wentworth also recently made the following trade(s):

• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $19.96 on Thursday. The company’s 50-day moving average is $16.62 and its 200-day moving average is $15.85. The firm has a market capitalization of $746.90 million, a PE ratio of 12.55 and a beta of -0.26. Entrada Therapeutics, Inc. has a fifty-two week low of $10.75 and a fifty-two week high of $20.49.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping the consensus estimate of $0.65 by $0.90. The company had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. As a group, analysts expect that Entrada Therapeutics, Inc. will post 1.07 EPS for the current year.

Institutional Trading of Entrada Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its stake in Entrada Therapeutics by 427.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after acquiring an additional 13,742 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Entrada Therapeutics during the 1st quarter worth $79,000. Bank of New York Mellon Corp increased its position in shares of Entrada Therapeutics by 13.4% in the second quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock worth $1,787,000 after purchasing an additional 14,838 shares during the period. Finally, Rhumbline Advisers raised its stake in Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after purchasing an additional 7,452 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Oppenheimer increased their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright boosted their price target on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.